Monitor for initiation of a Phase 2b trial for imdusiran and for further AB-101 Phase 1 data in cHBV patients. Cash runway should be assessed in next quarterly filing.
Drugs in focus
ABUS drug pipeline →AB-101
● Neutral Named in this 8-K- Impact
- Phase
- Phase 1a/1b
- Time to market
- AB-101 is in Phase 1a/1b trials; even if development proceeds smoothly, a potential approval is likely several years away given the early stage and the need for larger Phase 2 and Phase 3 trials.
- Next catalyst
- None dated
What to watchThe next catalyst for ABUS is Q3 2026 earnings on November 11, 2026 (tomorrow), which may include updates on AB-101's clinical development plans now that the FDA hold is lifted. For AB-101 specifically, watch for the company to announce the next phase of clinical trials in chronic hepatitis B patients. The clinical hold lift removes a key overhang, but the drug remains early-stage with no pivotal readout or PDUFA date on the horizon.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1- T+0 · Nov 12 $4.03entry
- T+1 · 4d ago +1.49%α +1.85% · $4.09
- T+2 · todayOpen
- T+5 · in 2d Pending
- T+20 · in 24d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Arbutus Biopharma filed an 8-K posting an updated corporate presentation on its website. The presentation reviews clinical data for its HBV pipeline, including imdusiran and AB-101, and reports cash of $104.6M as of October 31, 2026. No new material financial or regulatory events were disclosed.
Key Facts
- Filed 8-K on November 12, 2026 to post an updated corporate presentation
- Cash and cash equivalents of $104.6M as of October 31, 2026
- Pipeline includes imdusiran (siRNA) in Phase 2a and AB-101 (oral PD-L1 inhibitor) in Phase 1
- Imdusiran Phase 2a data: 10 patients achieved functional cure; 46% (48/105) achieved functional cure or discontinued NA therapy
- AB-101 Phase 1 data: 84.6% of evaluable subjects at 40 mg achieved 100% PD-L1 receptor occupancy
- No related SAEs or safety-related discontinuations reported for imdusiran in repeat-dose cohorts
Financial Impact
Cash position of $104.6M as of October 31, 2026; no revenue or earnings data in filing
Risk Factors
- No new financial guidance or material business development disclosed
- Clinical-stage biotech with no approved products; relies on future trial results and regulatory outcomes
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001171843-26-007378 |
| Document: f8k_111226.htm | 0001171843-26-007378 |
| Document: 0001171843-26-007378-index-headers.html | 0001171843-26-007378 |
| Document: 0001171843-26-007378-index.html | 0001171843-26-007378 |
| Document: 0001171843-26-007378.txt | 0001171843-26-007378 |
Track record
25 reports on ABUS
3 of 6 bullish or bearish reports moved the stock their way by T+60. Best: +11.55% at T+20 after the Aug 12, 2026 report. 6 of 12 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $4.04 Now $4.04 −0.00% settles Feb 16
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $4.04 Now $4.04 −0.00% settles Feb 16
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $4.07 Now $4.04 −0.74% settles Feb 12
- Nov 12, 20264d ago 8-K Neutral 2/10 Viewing Entry $4.03 Now $4.04 +0.25% settles Feb 10
- Nov 10, 20266d ago 8-K Neutral 5/10 Entry $3.82 Now $4.04 +5.76% settles Feb 8
- Nov 10, 20266d ago Press Release Neutral 4/10 No price data
- Nov 6, 202610d ago Institutional Cluster Bearish 4/10 Entry $3.66 Now $4.04 −10.53% settles Feb 4
- Oct 22, 202625d ago 8-K Bullish 6/10 Entry $4.21 Now $4.04 −4.04% settles Jan 20
- Oct 22, 202625d ago Press Release Bullish 7/10 Entry $4.21 Now $4.04 −4.04% settles Jan 20
- Oct 7, 20265w ago SC 13G/A Neutral 3/10 Entry $4.18 Now $4.04 −3.35% settles Jan 5
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers